VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
VivoSim's NAMkind platform puts drug candidates into contact with diseased human donor tissue, asking whether they work in MASH and IBD before anyone enrolls
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.